论文部分内容阅读
近几年影像技术的进展并不能对早期胰腺癌做出诊断.为探索能早期诊断胰腺癌的非侵入性方法,研究出一系列肿瘤标志物.本文对最近发现的CA_(242)进行评价并将其与已确立的CA_(19-9)、CA_(50)和癌胚抗原(CEA)等肿瘤标志物进行比较.收集1986年4月至1991年5月间300例患者和30例健康者的血清标本进行肿瘤标志物测定.其中68例胰管癌,24例其它胰腺肿瘤,57例急性胰腺炎,29例慢性胰腺炎(CP),90例上消化道疾病,32例恶性肿瘤.CA_(242)采用DELFIA技术测定,临界值为
In recent years, advances in imaging technology have not been able to diagnose early pancreatic cancer. To explore a non-invasive method for early diagnosis of pancreatic cancer, a series of tumor markers have been developed. This article evaluated the recently discovered CA_(242). It was compared with established tumor markers such as CA 19-9, CA 50, and CEA. 300 patients and 30 healthy subjects were collected between April 1986 and May 1991. The serum samples were tested for tumor markers. Of these, 68 were pancreatic cancers, 24 were pancreatic tumors, 57 were acute pancreatitis, 29 were chronic pancreatitis (CP), 90 were upper gastrointestinal diseases, and 32 were malignant. (242) Determined by DELFIA technique, critical value